临床正常老年人脑淀粉样蛋白负荷升高相关因素分析
基于A4预防试验筛查数据,纳入4486名65-85岁临床正常老年人,采用Florbetapir淀粉样蛋白PET分类。29.5%为Aβ+,Aβ+与痴呆家族史和APOE ε4等位基因相关,但与多种既往报道的危险因素无关。Aβ+者认知筛查表现更差且日常认知功能下降报告更多。
要点
- 临床正常老年人中29.5%淀粉样蛋白PET阳性。
- Aβ+与痴呆家族史及APOE ε4等位基因相关。
- Aβ+者认知表现更差且日常认知下降报告更多。
核心结论
- 在临床正常老年人中,脑淀粉样蛋白升高与痴呆家族史和APOE ε4等位基因相关,但与多种其他既往报道的危险因素无关。
研究设计与样本
- 横断面研究,纳入A4研究2014年4月至2017年12月筛查数据,来自美国、加拿大、澳大利亚和日本67个中心,共4486名65-85岁临床正常且认知未受损的老年人。
主要发现
- 4486名参与者中1323名(29.5%)为Aβ+,Aβ+者年龄略大于Aβ-。
- Aβ+者痴呆家族史比例更高(3320 Aβ+ [74%] vs 3050 Aβ- [68%])。
- Aβ+者至少携带1个APOE ε4等位基因比例更高(2602 Aβ+ [58%] vs 1122 Aβ- [25%])。
- Aβ+者筛查时临床前阿尔茨海默认知复合测验表现更差,认知功能指数变化得分更高。
临床怎么用
- 在临床正常老年人中,痴呆家族史和APOE ε4携带状态提示淀粉样蛋白升高风险较高,可考虑进一步评估。
- 淀粉样蛋白升高者虽临床正常,但认知测验表现更差且日常认知下降报告更多,需关注细微认知变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The Anti-Amyloid Treatment in Asymptomatic Alzheimer disease (A4) Study is an ongoing prevention trial in clinically normal older individuals with evidence of elevated brain amyloid. The large number of participants screened with amyloid positron emission tomography (PET) and standardized assessments provides an unprecedented opportunity to evaluate factors associated with elevated brain amyloid. OBJECTIVE: To investigate the association of elevated amyloid with demographic and lifestyle factors, apolipoprotein E (APOE), neuropsychological testing, and self- and study partner reports of cognitive function. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included screening data in the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease (A4) Study collected from April 2014 to December 2017 and classified by amyloid status. Data were was analyzed from 2018 to 2019 across 67 sites in the US, Canada, Australia, and Japan and included 4486 older individuals (age 65-85 years) who were eligible for amyloid PET (clinically normal [Clinical Dementia Rating = 0] and cognitively unimpaired [Mini-Mental State Examination score, ≥25; logical memory IIa 6-18]). MAIN OUTCOMES AND MEASURES: Screening demographics, lifestyle variables, APOE genotyping, and cognitive testing (Preclinical Alzheimer Cognitive Composite), self- and study partner reports of high-level daily cognitive function (Cognitive Function Index). Florbetapir amyloid PET imaging was used to classify participants as having elevated amyloid (Aβ+) or not having elevated amyloid (Aβ-). RESULTS: Amyloid PET results were acquired for 4486 participants (mean [SD] age, 71.29 [4.67] years; 2647 women [59%]), with 1323 (29.5%) classified as Aβ+. Aβ+ participants were slightly older than Aβ-, with no observed differences in sex, education, marital or retirement status, or any self-reported lifestyle factors. Aβ+ participants were more likely to have a family history of dementia (3320 Aβ+ [74%] vs 3050 Aβ- [68%]) and at least 1 APOE ε4 allele (2602 Aβ+ [58%] vs 1122 Aβ- [25%]). Aβ+ participants demonstrated worse performance on screening Preclinical Alzheimer Cognitive Composite results and reported higher change scores on the Cognitive Function Index. CONCLUSIONS AND RELEVANCE: Among a large group of older individuals screening for an Alzheimer disease (AD) prevention trial, elevated brain amyloid was associated with family history and APOE ε4 allele but not with multiple other previously reported risk factors for AD. Elevated amyloid was associated with lower test performance results and increased reports of subtle recent declines in daily cognitive function. These results support the hypothesis that elevated amyloid represents an early stage in the Alzheimer continuum and demonstrate the feasibility of enrolling these high-risk participants in secondary prevention trials aimed at slowing cognitive decline during the preclinical stages of AD.
引用
- Sperling RA, Donohue MC, Raman R, et al. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurol. 2020. PMID: 32250387. doi:10.1001/jamaneurol.2020.0387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。